Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

SRPT

Sarepta Therapeutics Inc

Jun 14 • 09:37AM ET

125.81

Dollar change +0.81
Percentage change 0.65	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IJH VTI VB VXF VBK MDY IBB XBI IJK IWP

Scroll to Statements

Index	-	P/E	1891.88	EPS (ttm)	0.07	Insider Own	6.10%	Shs Outstand	93.73M	Perf Week	2.02%
Market Cap	11.89B	Forward P/E	11.79	EPS next Y	10.67	Insider Trans	-0.48%	Shs Float	88.76M	Perf Month	-5.05%
Income	16.90M	PEG	-	EPS next Q	-0.12	Inst Own	87.22%	Short Float	7.32%	Perf Quarter	2.24%
Sales	1.40B	P/S	8.47	EPS this Y	160.96%	Inst Trans	6.35%	Short Ratio	5.01	Perf Half Y	36.59%
Book/sh	10.17	P/B	12.37	EPS next Y	201.68%	ROA	0.54%	Short Interest	6.49M	Perf Year	-3.53%
Cash/sh	14.71	P/C	8.55	EPS next 5Y	-	ROE	2.02%	52W Range	55.25 - 146.68	Perf YTD	30.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.21%	ROI	0.76%	52W High	-14.23%	Beta	0.85
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	32.89%	Gross Margin	85.20%	52W Low	127.71%	ATR (14)	5.00
Dividend Ex-Date	-	Current Ratio	4.05	EPS Y/Y TTM	101.12%	Oper. Margin	-6.76%	RSI (14)	52.00	Volatility	3.73% 3.85%
Employees	1314	Debt/Eq	1.44	Sales Y/Y TTM	43.83%	Profit Margin	1.20%	Recom	1.40	Target Price	165.90
Option/Short	Yes / Yes	LT Debt/Eq	1.33	EPS Q/Q	106.22%	Payout	-	Rel Volume	0.20	Prev Close	125.00
Sales Surprise	8.94%	EPS Surprise	2768.22%	Sales Q/Q	63.10%	Earnings	May 01 AMC	Avg Volume	1.29M	Price	125.81
SMA20	1.45%	SMA50	0.25%	SMA200	9.72%	Trades		Volume	17,575	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-24	Initiated	Piper Sandler	Overweight	$157
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$157 → $142
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187
Dec-22-22	Reiterated	BTIG Research	Buy	$125 → $160
Dec-16-22	Upgrade	UBS	Neutral → Buy	$100 → $158
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$140
Jan-05-22	Reiterated	Needham	Buy	$157 → $150
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform	$125
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight	$130
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy

Show Previous Ratings

Jun-13-24 04:04PM	Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test (Investor's Business Daily)
01:07PM	Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival (Barrons.com)
07:00AM	Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision (BioPharma Dive)
Jun-06-24 07:00AM	Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate (InvestorPlace)
May-31-24 05:45PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:31AM	Loading…
11:31AM	Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound? (Zacks)
May-29-24 05:48PM	Sarepta Therapeutics Set to Join S&P MidCap 400 (PR Newswire)
08:28AM	Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy? (Insider Monkey)
May-28-24 10:52PM	10 Best Fast Growth Stocks To Buy Now (Insider Monkey) -8.21%
May-24-24 11:57AM	Implied Volatility Surging for Sarepta (SRPT) Stock Options (Zacks)
May-23-24 07:10AM	The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now (InvestorPlace)
May-17-24 08:05AM	Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating (MT Newswires)
May-14-24 07:30AM	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180 (MT Newswires)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-03-24 10:07AM	Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health (Business Wire)
03:42PM	Loading…
May-02-24 03:42PM	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says (MT Newswires)
11:30AM	UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating (MT Newswires)
11:13AM	Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:08AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:52AM	Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating (MT Newswires)
06:01AM	Q1 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:32AM	Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-01-24 08:55PM	SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:30PM	Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30PM	Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript (Motley Fool)
05:20PM	Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates (Zacks)
05:06PM	Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours (MT Newswires)
04:19PM	Sarepta Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments (Business Wire)
09:15AM	1 Top Growth Stock to Buy and Hold for 10 Years (Motley Fool)
06:38PM	Loading…
Apr-30-24 06:38PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:28AM	Why Sarepta (SRPT) Might Surprise This Earnings Season (Zacks)
Apr-29-24 03:20PM	Sarepta Therapeutics Stock Shows Improved Technical Strength (Investor's Business Daily)
Apr-24-24 08:30AM	Sarepta Therapeutics to Announce First Quarter 2024 Financial Results (Business Wire) +6.09%
Apr-13-24 09:39PM	10 Unstoppable Stocks That Will Make You Richer (Insider Monkey)
Apr-08-24 04:13PM	Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst (Investor's Business Daily)
Apr-06-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in April (Motley Fool)
Apr-02-24 07:04AM	Outperforming ETF manager names a potential 50-bagger in the stock market (MarketWatch)
Mar-29-24 04:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-26-24 07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
Mar-25-24 10:00AM	A Comprehensive Look at Sarepta's Growth and Innovation (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 03:53PM	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
Mar-12-24 01:18AM	Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-11-24 09:03AM	Billionaire Ray Dalio and Insiders Love These 10 Stocks (Insider Monkey)
Mar-06-24 11:54PM	Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-04-24 09:47AM	Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst (Motley Fool)
08:30AM	Sarepta Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Mar-02-24 12:05AM	Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight (GuruFocus.com)
Feb-29-24 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.98%
12:35PM	Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
10:52AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
12:00AM	Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript (Motley Fool)
Feb-28-24 06:00PM	Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:23PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments (Business Wire)
07:15AM	Is It Too Late to Buy Sarepta Therapeutics Stock? (Motley Fool)
Feb-27-24 08:48AM	Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) (Zacks)
Feb-21-24 11:24AM	Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates? (Zacks)
08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-20-24 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-19-24 03:26AM	Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last? (Zacks)
Feb-16-24 11:23AM	Why Sarepta Therapeutics Stock Is Soaring Today (Motley Fool) +7.78%
11:22AM	Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again (Barrons.com)
08:46AM	UPDATE 3-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:41AM	CORRECTED-UPDATE 1-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:22AM	U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy (Reuters)
07:00AM	Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication (Business Wire)
Feb-15-24 07:45AM	2 Magnificent Growth Stocks to Buy With $500 (Motley Fool)
Feb-11-24 01:45AM	1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? (Motley Fool)
Jan-31-24 06:29PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-24 07:37AM	UPDATE 3-Sarepta's new Duchenne drug outperforms bestseller Exondys in trial (Reuters)
07:12AM	REFILE-Sarepta says its experimental Duchenne drug more effective than older medicine (Reuters)
07:00AM	Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 (Business Wire)
06:50AM	Sarepta data show new Duchenne drugs potency, but highlight side effects (BioPharma Dive)
Jan-26-24 05:15AM	Got $3,000? 3 Growth Stocks to Double Up On Right Now (Motley Fool)
Jan-25-24 09:45AM	Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
Jan-22-24 05:47PM	Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today (Motley Fool)
09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet (Zacks)
09:38AM	Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates (Insider Monkey)
Jan-16-24 03:57PM	Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market (InvestorPlace)
09:02AM	Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (Business Wire)
Jan-10-24 11:43AM	Sarepta Rebounded. Its Gene Therapy Is Back on Course. (Barrons.com)
06:17AM	Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains? (Zacks)
Jan-09-24 11:22AM	Why Is Sarepta Therapeutics (SRPT) Stock Up Today? (InvestorPlace) +16.72%
10:52AM	Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results (Zacks)
07:15AM	2 Growth Stocks That Could Make You Richer in 2024 and Beyond (Motley Fool)
Jan-08-24 11:55AM	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue (Business Wire) +5.41%
Jan-04-24 09:55AM	Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade (Zacks)
Jan-02-24 08:30AM	Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-29-23 06:27PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:44AM	Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Dec-28-23 10:07AM	3 Things About Sarepta Therapeutics Every Smart Investor Knows (Motley Fool)
Dec-27-23 06:26PM	15 Best Fast Growth Stocks to Buy Now (Insider Monkey)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
Dec-22-23 02:49PM	Sarepta Therapeutics Seen Expanding Duchenne Treatment Label (Barrons.com)
10:15AM	Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? (Motley Fool)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murray Dallan	Chief Customer Officer	May 02 '24	Sale	140.00	3,635	508,900	18,125	May 06 08:09 PM
Boor Kathryn Jean	Director	Mar 11 '24	Sale	122.93	761	93,550	7,516	Mar 11 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Option Exercise	13.90	15,000	208,500	37,840	Mar 11 08:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Sale	123.25	15,000	1,848,795	22,840	Mar 11 08:02 PM
Mayo Stephen	Director	Mar 05 '24	Sale	122.96	3,135	385,480	6,621	Mar 06 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Mar 01 '24	Sale	128.84	2,000	257,676	26,836	Mar 05 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Mar 01 '24	Sale	125.34	2,000	250,680	31,827	Mar 05 08:00 PM
Estepan Ian Michael	Chief Financial Officer	Mar 01 '24	Sale	128.30	1,200	153,960	39,114	Mar 05 08:00 PM
BEHRENS M KATHLEEN	Director	Nov 03 '23	Option Exercise	29.03	15,000	435,450	174,993	Nov 06 08:00 AM
Barry Richard	Director	Nov 03 '23	Buy	78.81	50,000	3,940,500	140,000	Nov 06 08:00 AM
INGRAM DOUGLAS S	President & CEO	Nov 03 '23	Buy	79.36	25,225	2,001,800	390,307	Nov 06 08:00 AM
Chambers Michael Andrew	Director	Aug 14 '23	Buy	109.47	9,979	1,092,429	246,996	Aug 15 08:00 AM
Chambers Michael Andrew	Director	Aug 11 '23	Buy	108.05	23,686	2,559,272	237,017	Aug 14 08:00 AM
Chambers Michael Andrew	Director	Aug 10 '23	Buy	106.15	34,867	3,701,067	213,331	Aug 11 07:40 AM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Option Exercise	29.03	15,000	435,450	35,994	Aug 08 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Sale	106.72	15,000	1,600,800	20,994	Aug 08 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience